M1 Medulloblastoma: high risk at any age

J Neurooncol. 2008 Dec;90(3):351-5. doi: 10.1007/s11060-008-9671-9. Epub 2008 Aug 15.

Abstract

Background: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defined.

Methods: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference.

Results: 55 patients were <3 years old and 230 patients were >or= 3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044).

Conclusions: Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Cerebellar Neoplasms / mortality*
  • Cerebellar Neoplasms / therapy*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Humans
  • Infant
  • Male
  • Medulloblastoma / mortality*
  • Medulloblastoma / therapy*
  • Prognosis
  • Retrospective Studies
  • Risk*
  • Survival Analysis
  • Young Adult